arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

Jason Grebely

3 papers · 2016–2025

2016: 12017: 02018: 02019: 02020: 02021: 02022: 12023: 02024: 02025: 1
2016peak 1 in 20162025

Frequent co-authors

Papers

showing 1–3 of 3 RSS

A Clarion Call to the Addiction Science Community: It's Time to Resist the Anti-scientific Policies of the US Trump Administration

Thomas F. Babor, Bryon Adinoff, Luke Clark +9 more

Artificial Intelligence · The Canadian Journal of Addiction · · cited 0× · DOI ↗ · more like this ·

This is a republished editorial that was originally published in Nordic Studies on Alcohol and Drugs.1 As a group of 28 addiction journal editors from 12 countries (This editorial is written by a group of 28 present and former editors of peer reviewed scientific journals specializing in the publication of addiction research. The authors have signed this editorial as individuals, not as representatives of any organization. Institutional affiliations are listed to demonstrate the authors’ academic credentials.), we are urgently drawing our readers’ attention to the abrupt and drastic changes in science policy now being enacted by the current US government. We are issuing a clarion call to the addiction science community to reverse the unethical, illegal and unscientific activities of the Trump Administration, and by analogy the activities of other governments that interfere with the…

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence

Michael Farrell (164574), Jeyran Shahbazi (14998872), Marianne Byrne (20238126) +9 more

Artificial Intelligence · Figshare · · cited 0× · OpenAlex ↗ · more like this ·

Background: Opioid agonist treatment (OAT) is an effective intervention for opioid dependence. Extended-release buprenorphine injections (BUP-XR) may have additional potential benefits over sublingual buprenorphine. This single-arm trial evaluated outcomes among people receiving 48 weeks of BUP-XR in diverse community healthcare settings in Australia, permitting examination of outcomes when BUP-XR is delivered in standard practice. Methods: Participants were recruited from a network of specialist public drug treatment services, primary care and some private practices in three states. Following a minimum 7 days on 8–32 mg of sublingual buprenorphine (±naloxone), participants received monthly subcutaneous BUP-XR injections administered by a healthcare practitioner and completed monthly research interviews. The primary endpoint was retention in treatment at 48 weeks. Findings: Participants…

2

Harout K. Tossonian, Jesse D. Raffa, Jason Grebely +7 more

Anthropology · · cited 0× · OpenAlex ↗ · more like this ·

Abstract: To evaluate the impact of mutations at reverse transcriptase codon 135 on treatment outcomes in patients re-ceiving NNRTI-based antiretroviral therapy, a total of 68 patients (30 with and 38 without baseline mutations at codon 135) were evaluated. Median increases in CD4 counts were 135 and 90 cells/mm 3 (p=0.32), virologic suppression (HIV RNA < 400 copies/mL) was achieved in 16 (53%) and 16 (42%) patients (p=0.50), while NNRTI resistance was detected in 10/14 (71%) and 16/22 (73%) in patients with and without mutations at codon 135, respectively. Patients who experi-enced a virologic breakthrough and had a baseline mutation at codon 135 were more likely to evolve a single NNRTI re-sistance mutation (8/14 vs 4/22, p=0.029) but less likely to evolve multiple NNRTI resistance mutations (2/14 vs 12/22, p = 0.033). Mutations at codon 135 do not affect response rates, but…